Prof. Richard Kao
Associate Professor
Department of Microbiology, The University of Hong Kong
biography
Professor Kao received his Ph.D. in Microbiology from the University of British Columbia (UBC) under the supervision of Professor Julian Davies and subsequently completed postdoctoral training at Harvard Medical School from 1999 to 2001. He joined the University of Hong Kong in 2001 and is now a tenured Associate Professor in the Department of Microbiology.
His research focuses on the application of chemical genetics to infectious diseases, with studies spanning SARS-CoV, influenza viruses, pathogenic bacteria and fungi. More recently, Professor Kao has extended his chemical genetic studies to bacterial virulence and antibiotic resistance, demonstrating the potential of non-antibiotic antivirulence compounds to treat MRSA infections. He has published extensively in journals such as Frontiers in Microbiology, mBio, PNAS, Nature Communications and Nature Biotechnology.
Professor Kao received the Innovation Academy Award from the International Consortium on Prevention and Infection Control (ICPIC) in Geneva, Switzerland, in 2017, the 2018 Chinese Medical Association China Science and Technology Award, and the 2019 State Scientific and Technological Progress Award. He was also a member of the team awarded the Royal Society of Chemistry’s 2023 Dalton Horizon Prize.
Title
Antivirulence Therapy: A Way Forward Against Antimicrobial Resistance?
Disarming Staphylococcus aureus—from Invasive Infection to Atopic Dermatitis
abstract
Antibiotics transformed infection management, but rising antimicrobial resistance (AMR) and a limited discovery pipeline demand complementary therapeutic strategies. Alongside phages, antibodies, microbiome interventions and antibiotic potentiators, antivirulence therapy offers a distinct approach: disabling bacterial disease mechanisms rather than targeting viability alone.
Drawing on research from the University of Hong Kong, this talk will examine antivirulence strategies against Staphylococcus aureus, including methicillin-resistant S. aureus (MRSA). Targeting staphyloxanthin-mediated immune evasion, ClpP and Agr/SaeR-dependent virulence regulation illustrates how bacterial disarmament can reduce pathogenicity, facilitate immune clearance and improve outcomes in experimental infection models. Antivirulence–antibiotic combinations further demonstrate that therapeutic benefit can extend beyond conventional growth-inhibition synergy to limiting pathogen-mediated host damage.
The discussion will span invasive infection and superficial skin disease, with particular attention to S. aureus-associated atopic dermatitis. Although atopic dermatitis is a multifactorial inflammatory disorder, staphylococcal toxins and proteases can exacerbate barrier dysfunction, inflammation and itch. Emerging topical approaches therefore aim to interrupt this cycle by suppressing bacterial virulence rather than relying on host immunosuppression or indiscriminate bacterial eradication. Together, these findings support antivirulence therapy as a promising, potentially antibiotic-sparing strategy, while highlighting the need to translate experimental efficacy into demonstrated clinical benefit.
